Summary of Verve Therapeutics (VERV) FY Conference Call - June 09, 2025 Company Overview - **Company**: Verve Therapeutics - **Focus**: Gene editing for cardiovascular disease, specifically targeting lifelong cholesterol lowering to treat coronary heart disease Key Points and Arguments 1. **HEART-two Data Announcement**: The company recently disclosed data from the HEART-two trial, which showed promising results for their gene editing therapy aimed at lowering LDL cholesterol levels [3][4] 2. **Unmet Need**: Current cholesterol-lowering therapies have a high dropout rate, with up to 50% of patients discontinuing treatment within a year. Verve aims to provide a one-time therapy that offers lifelong efficacy [5] 3. **Efficacy Results**: In the HEART-two trial, the therapy demonstrated an LDL reduction of up to 60%, with a mean reduction of 59% in the highest dose group. All patients in this group experienced over 50% lowering [8][21] 4. **Safety Profile**: The therapy was well tolerated, with only one infusion-related reaction reported among 14 patients. No significant laboratory abnormalities were observed [8][9] 5. **Durability of Effect**: The company reported that the LDL reduction was sustained at 60% two years post-infusion, supporting the vision of a one-time therapy for atherosclerotic cardiovascular disease [10][11] 6. **Comparison of Products**: The difference between the first-generation product (VRRB101) and the second-generation product (VRRB102) lies in the delivery system, which has been improved to enhance safety and efficacy [12][14] 7. **Regulatory Environment**: Recent discussions with the FDA indicate a supportive stance towards gene editing technologies, particularly those addressing chronic diseases like atherosclerosis [45][48] 8. **Market Research Findings**: Surveys indicate a significant openness among patients and physicians towards a one-time gene editing therapy, with about one-third of patients preferring this option over traditional therapies [50][53] 9. **Cost of Manufacturing**: The estimated cost to manufacture the therapy is around $3 per dose, suggesting potential for flexible pricing strategies compared to traditional gene therapies [55][56] 10. **Partnership with Eli Lilly**: The company is preparing to present data to Eli Lilly for potential opt-in for further development, which could extend Verve's cash runway [62][69] Additional Important Insights - **Dosing Strategy**: The company is shifting towards fixed dosing rather than weight-based dosing, as the therapy primarily targets the liver [24][26] - **Long-term Safety Considerations**: The company believes that the low risk of off-target effects, combined with the significant risk of untreated cardiovascular disease, will favor the adoption of their therapy [40][41] - **Future Developments**: Verve is also working on additional products targeting ANGPTL3 and Lp(a), leveraging the same delivery system as VRRB102 [64][66] This summary encapsulates the critical insights from the conference call, highlighting the company's innovative approach to gene editing in cardiovascular disease and its potential impact on patient care and market dynamics.

Verve Therapeutics (VERV) 2025 Conference June 04, 2025 09:20 AM ET Speaker0 Okay. Welcome everyone to twenty twenty five Jefferies Global Healthcare Conference. It it is my my name is Roger Song, one of the senior analysts covers MidCap biotech in US. And then it's my pleasure to have the next five star chat with our company, Zach, from the so excuse me. So from the Verve Therapeutics. So it it is a it is it is a very exciting timing for Verve because they just reported a very exciting data from the one tw ...

NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upco ...

Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entered into a se ...

Esperion Therapeutics (ESPR) FY 2025 Conference May 20, 2025 10:00 AM ET Speaker0 Okay. Welcome back, everybody. My name's Joe Panginas, managing director here at, HC Wainwright. Very happy to have with us Esperion Therapeutics. And, also nice to have the second commercial stage, company that I'm, doing a fireside chat with today. So it's very refreshing in the small cap biotech space, which, you don't necessarily apply to. So presenting for the company is Ben Halliday, chief financial officer. Ben, thank y ...

Esperion Therapeutics (ESPR) 2025 Conference May 08, 2025 12:30 PM ET Speaker0 I guess take a step back and Primary. I guess take a step back and go go through the data that went into those new labels. Can you just walk us through the clear outcome study and the findings there? Speaker1 So the clear outcome study was a 14,000 patient outcome study which measured MACE four, MACE three in a variety of endpoints in both a, in a non statin population in both a primary and secondary prevention patient population ...

– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively -- -- Company to host R&D day on June 11th, 2025 in New York City -- –$808.5 million in cash, cash equivalents and marketable securities at March 31, 2025 – NAARDEN, The Netherlands and MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasda ...

– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with HLS Therapeutics (TSX:HLS) for the exclusive rights to ...

Amarin Corporation (AMRN) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Mark Marmur - VP, Global Corporate Comunications & IRAaron Berg - CEO, President & DirectorPeter Fishman - SVP & CFOAdam Ferrarini - Biotech Equity Research AssociateSteven Ketchum - Executive VP, President of Research & Development and Chief Scientific Officer Conference Call Participants None - Analyst Operator Welcome to Amarin Corporation's conference call to discuss its first quarter twenty twenty five busines ...

Amarin Corporation (AMRN) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Speaker0 Welcome to Amarin Corporation's conference call to discuss its first quarter twenty twenty five business update and financial results. I would like to turn the conference call over to Mark Marmer, Vice President, Corporate Communications and Investor Relations at Amarin. Speaker1 Good morning, everyone, and thank you for joining us. Turning to slide two and our forward looking statements. Please be aware that this conference c ...